StockData
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. (ERNA) stock

ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.62−0.01 (-0.61%)

Close on Nov 18, 2026Market cap $2.64MP/E –Yield –

Ernexa Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Ernexa Therapeutics's gross profit for the twelve months ending Dec 31, 2024 was $486.00K. For fiscal 2024 it was $486.00K.

Annual gross profit

PeriodPeriod endValueChange
FY2024Dec 31, 2024$486.00K–
FY2023Dec 31, 2023-$168.00K–
FY2022Dec 31, 2022$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$1.00K–
Q3 FY2024Sep 30, 2024$547.00K–
Q2 FY2024Jun 30, 2024-$48.00K–
Q1 FY2024Mar 31, 2024-$14.00K–
Q4 FY2023Dec 31, 2023-$49.00K–
Q3 FY2023Sep 30, 2023-$69.00K–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023-$50.00K–
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–

More Ernexa Therapeutics figures

See a number that looks wrong?